Study guide
4.1 Publication Agreements, Review Rights, Compensation & Disclosure
Certified Medical Publication Professional CMPP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Preparation Strategy
1.1 ISMPP CMPP Certification Overview, Eligibility & Exam Format 1.2 Recertification, Continuing Education (CE) Credits & ISMPP U 1.3 Core Reference Hierarchy, Primary Documents & Test-Taking Strategy
2 Chapter 2: Publication Planning: Strategy, Environment & Scientific Platform
2.1 Medical Publication Lifecycle & Strategic Planning Frameworks 2.2 Therapeutic Landscape Analysis, Unmet Needs & Gap Analysis 2.3 Scientific Communication Platforms and Evidence-Based Language
3 Chapter 3: Publication Planning: Governance, Steering Committees & Venue Selection
3.1 Publication Steering Committees: Charters, Roles & Scientific Governance 3.2 Target Audience Identification: HCPs, Patients, Payers & Regulators 3.3 Venue Selection, Open Access, and Congress Strategy
4 Chapter 4: Publication Planning: Operations, Contracting, Global Alignment & Compliance
4.1 Publication Agreements, Review Rights, Compensation & Disclosure 4.2 Milestones, Gantt Charts, Budgeting & Vendor/Agency Management 4.3 Global vs. Regional/Local Publication Alignment & Localization 4.4 Publication SOPs, Documentation, Quality Control & Audit Readiness
5 Chapter 5: Reporting Guidelines: Foundational Standards & Trial Reporting
5.1 EQUATOR and Design-Specific Reporting Guidelines 5.2 CONSORT 2025 & Flow Diagrams for Randomized Trials 5.3 SPIRIT 2025: Standard Protocol Items for Interventional Trials
6 Chapter 6: Reporting Guidelines: Observational, Reviews & Preclinical
6.1 PRISMA 2020 for Systematic Reviews & Meta-Analyses 6.2 STROBE & RECORD for Observational and Routinely Collected Data 6.3 ARRIVE 2.0 for In Vivo Animal Research
7 Chapter 7: Specialized Reporting, Plain Language Summaries & Congress Submissions
7.1 STARD 2015, CARE, and Specialized Reporting Guidelines 7.2 Plain-Language Summaries and Patient Partnership 7.3 GPCAP 2026: Congress Abstracts, Presentations & Encores 7.4 Digital Publication Features, Accessibility, and Social Dissemination
8 Chapter 8: Manuscript Lifecycle: Drafting, Peer Review, Open Access & Metrics
8.1 Manuscript Development, Author Review, and Sponsor Boundaries 8.2 Peer Review, Rebuttals, Revisions, and Appeals 8.3 Preprints, Creative Commons & Current Open-Access Requirements 8.4 Post-Publication Metrics and Correcting the Record
9 Chapter 9: Ethical Principles: GPP 2022, Authorship Criteria & Contributorship
9.1 Good Publication Practice 2022: Principles, Scope & Application 9.2 ICMJE Authorship Criteria and Qualification Scenarios 9.3 Nonauthor Contributors, Acknowledgments, and CRediT
10 Chapter 10: Ethics & Transparency: Ghostwriting, Writing Assistance, COI & Disclosure
10.1 Ghostwriting, Guest Authorship, and Authorship Disputes 10.2 Professional Medical Writing: Roles, Authorship, Disclosure & Funding 10.3 Disclosure of Interests and Publication Transparency 10.4 Open Payments, EFPIA Codes & Publication-Related Transfers of Value
11 Chapter 11: Compliance & Legal: Clinical Trial Registration, Data Sharing, Regulatory & Ethics
11.1 Trial Registration and Results Disclosure: US, EU, and ICMJE 11.2 Clinical-Trial Data-Sharing Statements and FAIR Principles 11.3 FDA SIUU Guidance & Promotional/Scientific Communication Boundaries 11.4 2024 Declaration of Helsinki, Ethics Review, Privacy & Copyright
4.1 Publication Agreements, Review Rights, Compensation & Disclosure
Key Takeaways Explain This Topic AI
The signed clinical trial agreement, protocol, publication policy, author agreement, and venue rules—not a presumed industry-standard clause—govern publication rights and sequencing.
Agreements should protect timely dissemination while defining reasonable sponsor review for factual accuracy, confidentiality, intellectual property, regulatory or legal issues, and other legitimate responsibilities.
Authorship and editorial conclusions remain based on contribution, evidence, approval, and accountability; sponsor funding does not create an unlimited veto.
GPP 2022 permits reasonable compensation for legitimate work in appropriate circumstances but rejects payment for a byline or influence; applicable transparency and disclosure rules still apply.
Publication, conflict-of-interest, and transfer-of-value disclosures are separate but coordinated obligations that require accurate records.
Last updated: October 2026
Publication Agreements, Review Rights, Compensation & Disclosure
Note
Publication professionals should read the actual governing documents. There is no universal clinical trial agreement clause, pooling period, sponsor review window, patent delay, or compensation rule that can be assumed without checking the contract and applicable policy.
Agreements That May Apply
A company-sponsored publication may be affected by several documents:
- Document Typical role
- Clinical trial agreement (CTA) Rights and duties between sponsor and site or institution
- Protocol Study conduct and dissemination commitments
- Publication policy or plan Program-wide governance and sequencing
- Steering-committee charter Decision process and dispute escalation
- Author or contributor agreement Roles, criteria, review, approval, compensation, disclosure
- Agency statement of work Writing, project management, quality control, deliverables
- Data-use agreement Access, privacy, security, permitted analysis
- Journal or conference terms Submission warranties, disclosure, copyright, licensing
They must be read together. If terms conflict, escalate to the responsible legal, compliance, contracting, or governance function rather than inventing a compromise.
Publication Rights and Multicenter Sequencing
Multicenter CTAs often coordinate site-level publication with the primary pooled report. The purpose can be scientifically legitimate: premature single-site reporting may disclose an incomplete picture, create biased subgroup claims, or interfere with the planned primary analysis.
But the exact rule is contractual. It may allow a site publication after:
- the multicenter paper is published;
- the multicenter paper is submitted or accepted;
- the sponsor or writing group declines to publish;
- a specified period expires;
a steering committee approves a scientifically distinct analysis.
Do not assume a standard 12-to-18-month pooling clause. Review the signed agreement and protect the investigator's residual right to publish. A clause that permits indefinite suppression should be escalated and evaluated against law, ethics, funder commitments, and publication-practice standards.
Sponsor Review
A sponsor can have legitimate review responsibilities. A prospectively defined review may address:
- factual accuracy against validated data;
- confidential information;
- patentable inventions;
- regulatory or legal risk;
- privacy;
- required safety context;
- compliance with an agreement;
completeness of sponsor-role and funding disclosure.
Review does not equal editorial ownership. Authors should consider relevant comments but remain responsible for their scientific interpretations and final approval. The sponsor should not remove an unfavorable prespecified result, demand a claim unsupported by the analysis, choose authors for prescribing influence, or impose delay for product positioning.
The duration and process should be reasonable and written. GPP 2022 does not establish a universal 30-day review or 60-to-90-day patent delay. The agreement and circumstances control, subject to the principle of timely dissemination.
Intellectual Property
Public disclosure can affect patent rights, so a limited prepublication review for patentable material can be appropriate. Plan early enough to file without unnecessary delay. A temporary hold should be tied to a real filing activity and the agreed process, not to waiting for a patent to issue or a product to launch.
Separate patent review from copyright. Patent protection concerns inventions before disclosure; copyright and licensing concern expression and reuse of the publication.
Author Agreements
A good author agreement communicates:
- anticipated contributions and authorship criteria;
- that byline status depends on actual contributions;
- author access to relevant information;
- review responsibilities and timelines;
- final approval and accountability;
- disclosure obligations;
- professional writing support;
- data-check responsibilities;
- procedures for withdrawal, unresponsiveness, disputes, or authorship changes;
- expense reimbursement and any compensation policy;
archiving and communication expectations.
An agreement cannot make a nonqualifying contributor an author. It can, however, create a fair process and give each proposed author the opportunity to meet the criteria.
Compensation
Distinguish payment for authorship from compensation for legitimate work .
Payment merely for placing a name on a byline, endorsing a conclusion, prescribing, or lending prestige is unethical. GPP 2022's official FAQs explain, however, that reasonable compensation for actual publication activities may be permissible in some circumstances. Examples can include steering-committee work, new analysis or interpretation, manuscript review, or patient-partner contributions.
The arrangement must be:
- for defined services, not for a name;
- reasonable and consistent with applicable fair-market-value controls;
- permitted by law, institutional policy, contract, and company policy;
- communicated clearly, preferably in the agreement;
- reported through Open Payments or another transparency system when applicable;
disclosed to the venue as required.
Compensation does not automatically qualify or disqualify authorship. Apply authorship criteria separately.
Financial and Nonfinancial Disclosure
Publication disclosure may require:
- study funding;
- sponsor role;
- individual financial relationships;
- relevant institutional support;
- patents or intellectual property;
- nonfinancial interests requested by the venue;
- professional writing or editorial support and its funding;
data-access or analysis roles.
Use the current journal or conference form and each author's own complete disclosure. Do not copy a disclosure from an earlier article without reconfirmation.
Transfer-of-Value Coordination
A payment can be reportable even if it is ethically permissible, and an unreported relationship can still require journal disclosure. Open Payments, EFPIA-related processes, national transparency law, institutional disclosure, and journal disclosure have different scopes.
For each arrangement, preserve:
- agreement and statement of work;
- service description;
- dates and attendees;
- recipient details;
- invoices and expense records;
- fair-market-value documentation where required;
- reporting classification;
publication disclosure.
Do not assume professional writing activity is always excluded from Open Payments. CMS says research writing and publication activity is included when it is in the written research agreement or protocol and paid as part of the research payment.
Dispute Scenario
A site investigator wants to publish a single-center analysis before the pooled multicenter report. The correct first steps are to:
- read the signed CTA and publication policy;
- determine whether the analysis is scientifically distinct and sufficiently powered;
- assess risk to the primary report and participant confidentiality;
- use the stated governance and escalation process;
preserve the investigator's contractual publication right when any defined coordination period ends.
It is not defensible to announce that a “standard” pooling clause automatically prohibits the work for 18 months.
Safety-Data Scenario
If a sponsor function requests deletion of a prespecified hepatic safety result because it may affect positioning, the request should be rejected and escalated. The manuscript should report the validated finding with appropriate context. Sponsor review may improve factual accuracy, but it may not turn the scientific record into a selective marketing narrative.
Important
In agreement questions, choose the answer that reads the controlling documents, permits legitimate review, protects timely and complete reporting, preserves author accountability, and discloses relationships. Avoid answers built on a made-up universal timeframe or categorical compensation ban.